Drug Index


Mechanism :

Etelcalcetide, a synthetic peptide calcimimetic, allosterically activates the calcium-sensing receptor (CaSR) on the parathyroid gland, resulting in decreased PTH secretion, and serum calcium and phosphorus levels in patients with secondary hyperparathyroidism on hemodialysis.

Indication :

  • Secondary hyperparathyroidism with chronic kidney disease (CKD) on hemodialysis

Contraindications :

Hypersensitivity to etelcalcetide or any component of the formulation.

Dosing :

Safety and efficacy not established in children.
IV: Initial: 5 mg IV bolus 3 times per week at the end of hemodialysis.

Adverse Effect :

Decreased serum calcium, hypophosphatemia, diarrhea, nausea, muscle spasm, prolonged Q-T interval on ECG, cardiac failure, hypocalcemia, vomiting, antibody development.

Interaction :

Cinacalcet: May enhance the hypocalcemic effect of Etelcalcetide.

Hepatic Dose :

No dosage adjustments are recommended.
02/22/2024 11:41:26 Etelcalcetide
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0